Floatz logo

Pyrotinib

Lung Squamous Cell Carcinoma

SOLTI Breast Cancer Research GroupSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Lung Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Vinorelbine
AbbVie
Phase 3BB
Veliparib
AbbVie
Phase 3BB
Irinotecan
AstraZeneca
Phase 3BB
(+)-VINCRISTINE
AstraZeneca
Phase 3BB
PEGFILGRASTIM
Wake Forest University Health Sciences
Phase 2B

View all 18 →

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →